Estrogen Explained — The Three Types, the Five Dysfunction Patterns, and Why Most Women Are Getting Incomplete Information
Ask most women what they know about estrogen and you will get one of two answers.
The first: estrogen is the hormone you lose at menopause. It causes hot flashes when it drops. You might take HRT to replace it.
The second — increasingly common among women who have found hormonal health education online: estrogen is dangerous when elevated. It drives endometriosis, fibroids, PMDD, and weight gain. It needs to be cleared.
Both answers are incomplete. And the incompleteness of each is causing real harm — either to women suffering genuine estrogen deficiency without support, or to women experiencing estrogen dominance without understanding that the problem is not estrogen itself but what their body is doing with it.
The complete picture is more nuanced — and more useful — than either framing suggests.
The Three Estrogens — What They Are and When Each Is Dominant
"Estrogen" is a family of hormones, not a single molecule. Understanding which estrogen is dominant at which life stage, and what each one does, is the starting point for any clinically meaningful conversation about estrogen.
Estradiol (E2) — The Powerhouse of Reproductive Years
Estradiol is the most potent and biologically active of the three estrogens. Produced primarily by the granulosa cells of the ovarian follicles during reproductive years, it is the estrogen responsible for the vast majority of what we call "estrogen's effects" — on the brain, bones, cardiovascular system, skin, gut, immune system, and metabolic function.
Estradiol modulates serotonin and dopamine receptor density in the brain, protects hippocampal memory function, promotes myelin integrity, maintains the elasticity of blood vessel walls, inhibits osteoclast-driven bone breakdown, supports insulin sensitivity, and governs the immune modulation that gives premenopausal women their cardiovascular advantage over men.
When estradiol declines at menopause, all of these systems are affected simultaneously — which is why menopause is a whole-body event, not merely a gynecological one.
Estrone (E1) — The Post-Menopausal Estrogen
Estrone becomes the dominant circulating estrogen in post-menopausal women. It is produced primarily in adipose (fat) tissue through the conversion of adrenal androgens — specifically androstenedione — by the aromatase enzyme. It is significantly less potent than estradiol but remains biologically active.
Post-menopausal women with higher adipose tissue produce more estrone through this aromatase pathway — which is one mechanism by which estrogen dominance can persist and even worsen after menopause, despite the cessation of ovarian estrogen production. The woman who is told her estrogen should be low post-menopause but continues to experience estrogen-dominant symptoms is frequently experiencing elevated estrone from peripheral aromatization.
Estriol (E3) — The Protective Estrogen
Estriol is the weakest of the three estrogens and is produced in significant quantities primarily during pregnancy, where it serves protective roles for both mother and fetus. Outside of pregnancy, it circulates at very low levels.
Estriol has a distinctly less proliferative receptor activity profile than estradiol and estrone — it competes for estrogen receptors with lower activation potency, producing a net anti-estrogenic effect in some tissues when present alongside more potent estrogens. This is why estriol is used in some compounded bioidentical hormone formulations and topical vaginal preparations: its weaker receptor activation profile makes it therapeutically useful in contexts where gentle estrogen activity is desired without the proliferative burden of estradiol.
The Five Estrogen Dysfunction Patterns — Which One Applies to You
Understanding which estrogen dysfunction pattern is actually present is the essential prerequisite for choosing an appropriate intervention. Each pattern requires a different approach. A woman treating pattern 1 with the interventions for pattern 2 will not get better — and may get worse.
Pattern 1: Estrogen Deficiency
The classic late perimenopause and post-menopause picture. Estradiol production from the ovaries has declined significantly, producing: vasomotor symptoms (hot flashes, night sweats), cognitive changes (word-finding difficulty, processing slowdown), mood instability, sleep disruption, vaginal dryness and atrophy, bone density loss, and cardiovascular risk elevation.
This pattern requires estrogen support — either through hormone therapy or through botanical support that works through estrogen-adjacent pathways. Botanicals with documented relevance to estrogen deficiency include:
Maca (Lepidium meyenii) — an adaptogenic root with demonstrated effects on hot flash frequency and intensity and on subjective menopausal symptom burden, working through endocrine modulation rather than direct phytoestrogenic activity.
Red clover (Trifolium pratense) — contains isoflavones (biochanin A, formononetin, daidzein, genistein) that bind to estrogen receptors with lower activation potency than estradiol, producing modest estrogenic effects that can partially compensate for deficiency without the proliferative burden of full estrogen receptor activation.
Wild yam (Dioscorea villosa) — traditionally used as a precursor support for steroid hormone synthesis. Contains diosgenin, a steroidal saponin from which progesterone and estrogen are synthesized commercially, though the conversion of dietary diosgenin to active hormones in the human body is not well-established in the research literature.
Chaste tree berry (Vitex agnus-castus) — supports pituitary hormone regulation in ways that can influence the overall estrogen-progesterone balance, particularly relevant in peri- and post-menopausal women whose pituitary-ovarian signaling has become dysregulated.
Pattern 2: Estrogen Dominance
The early perimenopause and reproductive-age picture. Estrogen is not deficient — it is present at normal or elevated levels, but progesterone is insufficient to counterbalance it. The ratio is off, not the absolute estrogen level.
Estrogen dominance drives: heavy and painful periods, PMDD, endometriosis activity, fibroid growth, ovarian cyst formation, breast tenderness, bloating, mood instability in the luteal phase, and the worsening premenstrual symptom trajectory that characterizes the progesterone-first shift of early perimenopause.
This pattern requires progesterone restoration (chaste tree berry, cortisol reduction via ashwagandha to stop pregnenolone steal) and estrogen clearance support — not estrogen reduction per se, and certainly not additional estrogenic botanicals.
Pattern 3: Metabolic Dysfunction — The 2-OH to 16α-OH Ratio Problem
Estrogen production and absolute levels are normal; progesterone is adequate; but estrogen is being metabolized primarily through the 16-alpha-hydroxy pathway, producing potent, proliferative metabolites that stimulate estrogen-sensitive tissue more aggressively than the cleaner 2-hydroxy metabolites.
A woman with this pattern has estrogen-driven symptoms disproportionate to her measured hormone levels — because the problem is in the quality of her estrogen metabolism, not the quantity. Standard hormone panels will be unremarkable. A Physicians Lab 24-hour Comprehensive Urinary Metabolite Profile showing the 2-OH to 16α-OH ratio will reveal the problem.
DIM addresses this pattern directly — it induces CYP1A1 and CYP1A2 enzymes that promote 2-hydroxylation, shifting the metabolic balance toward safer, less proliferative estrogen metabolites. Sulforaphane contributes through phase II enzyme upregulation that facilitates clearance of whichever metabolites are produced.
Pattern 4: Clearance Failure — Gut Estrogen Reabsorption
Estrogen is produced in appropriate amounts and metabolized through healthy pathways, but the liver's conjugation products are being broken down in the gut by elevated beta-glucuronidase activity — allowing estrogen to be reabsorbed into circulation rather than eliminated. This can raise total estrogen exposure significantly above what ovarian production alone would suggest.
Beta-glucuronidase elevation is driven by gut dysbiosis, high-fat diets, chronic stress, and antibiotic use. The result is a cycle: estrogen that should have been eliminated on one pass through the liver returns to circulation, drives additional estrogenic tissue stimulation, and must be cleared again in subsequent cycles.
Calcium D-glucarate is the specific intervention for this pattern — it inhibits beta-glucuronidase directly, allowing the liver's conjugated estrogen to survive the intestinal journey intact and complete elimination.
Pattern 5: Binding Dysfunction — TBG and SHBG Elevation
Total estrogen measures are adequate; metabolism and clearance are functioning; but estrogen availability at the cellular level is reduced because an elevated proportion is bound to carrier proteins — thyroid binding globulin (TBG) in the case of the thyroid-estrogen connection discussed in the thyroid blog post, or sex hormone binding globulin (SHBG) more broadly.
This pattern is typically driven by estrogen dominance itself (elevated estrogen drives SHBG production), by progesterone deficiency (which normally opposes TBG elevation), and by the hormonal shifts of perimenopause and menopause. Addressing the underlying estrogen-progesterone ratio is the primary intervention; restoring progesterone through chaste tree berry and cortisol reduction helps maintain more free, active hormone in circulation.
How Vita-Fem Addresses Each Pattern
Vita-Fem Cycle Perimenopause Supplement addresses Patterns 2, 3, and 4 — the estrogen dominance, metabolic dysfunction, and clearance failure patterns that characterize early perimenopause and estrogen-dominant conditions across the reproductive age range.
The calcium D-glucarate + DIM + sulforaphane triad was built specifically for these three patterns, addressing them at three distinct biochemical points simultaneously. Chaste tree berry and ashwagandha address Pattern 2 from the progesterone restoration direction.
Vita-Fem Restore Menopause Supplement addresses Pattern 1 — estrogen deficiency — through black cohosh for vasomotor support, epimedium for skeletal protection via osteoclast inhibition, and chaste tree berry for ongoing hormonal regulation, alongside the full five-hormone support structure that makes estrogen deficiency management more effective when cortisol, thyroid, progesterone, and testosterone are also addressed.
Frequently Asked Questions
What is the difference between estrogen dominance and estrogen deficiency?
Estrogen deficiency is insufficient estrogen producing hot flashes, bone loss, and cognitive changes — the late perimenopause and menopause picture. Estrogen dominance is insufficient progesterone relative to estrogen — even at normal estrogen levels — producing heavy periods, PMDD, fibroids, and mood instability. They require different interventions. Treating deficiency with dominance interventions, or dominance with deficiency interventions, will not produce the intended result.
What are the three types of estrogen in women?
Estradiol (E2) — most potent, dominant in reproductive years, governs brain, bone, cardiovascular, and metabolic function; Estrone (E1) — dominant post-menopause, produced in fat tissue via aromatase; Estriol (E3) — weakest, produced significantly during pregnancy, used in some bioidentical formulations for its more protective receptor activity profile.
What is the 2-OH to 16-alpha-OH estrogen ratio and why does it matter?
Estrogen is metabolized through multiple pathways. The 2-OH pathway produces safer, largely inactive metabolites that are easily cleared. The 16α-OH pathway produces more potent, longer-acting metabolites that stimulate estrogen-sensitive tissue more aggressively. A woman whose metabolism skews toward 16α-OH experiences greater estrogen-driven symptom burden at the same absolute estrogen level. DIM shifts the ratio toward safer 2-OH metabolites.
Does DIM lower estrogen?
No. DIM does not reduce estrogen production. It shifts estrogen metabolism toward safer 2-OH metabolites and away from more proliferative 16α-OH metabolites — improving the quality of estrogen metabolism rather than reducing the quantity of estrogen. Women who need to reduce estrogen dominance generally need to shift their metabolite ratio and improve clearance, not suppress estrogen production.
What botanicals support estrogen deficiency at menopause?
Botanicals with documented relevance to estrogen deficiency include maca (adaptogenic, reduces hot flash frequency), red clover isoflavones (weak phytoestrogenic activity at estrogen receptors), and wild yam (traditional precursor support). These are included in the botanical support conversation for Pattern 1 (deficiency) and are distinct from DIM, calcium D-glucarate, and sulforaphane, which address patterns of excess or poor metabolism.
How does Vita-Fem Cycle address estrogen dominance?
Through three simultaneous mechanisms: calcium D-glucarate inhibits beta-glucuronidase to prevent gut estrogen reabsorption (Pattern 4); DIM shifts estrogen metabolism toward safer 2-OH metabolites (Pattern 3); sulforaphane activates Nrf2-dependent phase II liver detoxification for complete estrogen elimination (Pattern 3 and 4). Chaste tree berry and ashwagandha address Pattern 2 from the progesterone restoration direction.
